Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1489"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label |
"evidence_1651"
|
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_numb_subjects | |
| ?:Evidence_object_dose | |
| ?:Evidence_precip_dose | |
| ?:Evidence_type | |
| ?:Evidence_value | |
| ?:content |
"Route of administration: oral
study duration: venlafaxine for 4 days followed by 14 days of venlafaxine and aripiprazole
population: 27 (55% male)
mean age (SD):35 (7)
NOTE: aripiprazole dose was titrated over the 14 day period from 10mg/day to 20mg/day
AUC_i/AUC: 657/777 = 1.183 (geometric means)
Description:
Healthy subjects received venlafaxine 75 mg/day (Study 1; N = 38) or escitalopram 10 mg/day (Study 2; N = 25) with the addition of aripiprazole 10-20 mg/day (10 mg/day fixed dose in Study 2) for 14 days. ... In healthy subjects, point estimates [90% CI] for the ratios of geometric means of Cmax (venlafaxine 1.148 [1.083-1.217]; escitalopram 1.04 [0.99-1.09]) and AUCTAU (venlafaxine 1.183 [1.130-1.238]; escitalopram 1.07 [1.04-1.11]) indicated no meaningful increase in ADT exposure in the presence of aripiprazole."
|
| dc:creator | |
| dc:date |
"05/06/2009 14:34:29"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ aripiprazole_increases_auc_venlafaxine, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1651 }